Back

Zymeworks finalizes Theravance deal, forecasts 2026 revenue of $278 million-$292 million

Verifying
  • Zymeworks finalized its acquisition of Theravance Biopharma and issued 2026 financial guidance.
  • 2026 revenue is projected at $278 million-$292 million, with adjusted EBITDA of $114 million-$128 million.
  • YUPELRI hospital sales increased 25% in the second quarter of 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.